Healthcare · Medical - Diagnostics & Research
Price
$4.49
Market Cap
$4.9M
Employees
40
Beta
0.69
Avg Volume
436,546
CEO
Yi Lu
Business Description
Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.
Business History
Price Overview
Last updated: Jun 27, 2026 8:55am (just now)$4.49
-0.50 (-10.02%)
Day Range
$4.49 – $4.98
52-Week Range
$3.61 – $18.20
50-Day MA
$4.87
200-Day MA
$6.51
Volume
3,616.00
Share Structure
Outstanding
1,082,121.00
Float
154,152.00
Free Float
14.2%
Very low free float
— 14.2% of shares trade freely, ~85.8% held by insiders/institutions
Thinly traded — expect wider bid-ask spreads and sharp price swings on modest volume. Institutional investors may avoid due to liquidity constraints.
Small absolute float (0.2M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-47.87
Stock Price: $4.49
EPS (Diluted): -0.09
EPS (Diluted): -0.09
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
4.36
Stock Price: $4.49
Total Equity: $3.48M
Shares: 1,082,000
Total Equity: $3.48M
Shares: 1,082,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-4.78
Market Cap: $4.86M
Total Debt: $1.22M
Cash: $2.90M
EBITDA: -$83,401
Total Debt: $1.22M
Cash: $2.90M
EBITDA: -$83,401
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$13.5M
Market Cap: $4.86M
Total Debt: $1.22M
Cash: $2.90M
Total Debt: $1.22M
Cash: $2.90M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $4.49
Revenue: $0.00
Shares: 1,082,000
Revenue: $0.00
Shares: 1,082,000
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$10,711
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$94,112
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$101,524
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-65.1%
Net Income: -$101,524
Total Equity: $3.48M
Total Equity: $3.48M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-332.2%
Operating Income: -$94,112
Tax Rate: 0.0%
Equity: $3.48M
Total Debt: $1.22M
Cash: $2.90M
Tax Rate: 0.0%
Equity: $3.48M
Total Debt: $1.22M
Cash: $2.90M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.09
Current Assets: $6.03M
Current Liabilities: $2.89M
Current Liabilities: $2.89M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.35
Short-Term Debt: $1.08M
Long-Term Debt: $139,772
Total Debt: $1.22M
Total Equity: $3.48M
Long-Term Debt: $139,772
Total Debt: $1.22M
Total Equity: $3.48M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 1,082,000
Shares: 1,082,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$3.21
Total Equity: $3.48M
Shares: 1,082,000
Shares: 1,082,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.17
Operating CF: -$181,464
CapEx: -$985.00
Shares: 1,082,000
CapEx: -$985.00
Shares: 1,082,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $4.49
Stock Price: $4.49
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$101,524
Net Income: -$101,524
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ADVB against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 10:37am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $11,890 | $0 | $10,711 |
| Gross Profit | $0 | $0 | $-11,890 | $0 | $-10,711 |
| Operating Expenses | $1.8M | $2.4M | $88,094 | $2.5M | $83,401 |
| Operating Income | -$1.8M | -$2.4M | $-99,984 | -$2.5M | $-94,112 |
| Net Income | -$1.8M | -$4.0M | $-121,521 | -$2.8M | $-101,524 |
| EBITDA | -$1.8M | -$2.2M | $-88,094 | -$2.1M | $-83,401 |
| EPS | $-0.06 | $-0.13 | $-0.11 | $-0.08 | $-0.09 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 10:37am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $65,922 | $4.8M | $2.6M | $2.6M | $2.9M |
| Total Current Assets | $913,497 | $5.0M | $2.8M | $3.1M | $6.0M |
| Total Assets | $1.0M | $6.7M | $4.6M | $4.5M | $6.5M |
| Current Liabilities | $28,350 | $3.0M | $3.3M | $2.7M | $2.9M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $139,772 |
| Total Liabilities | $30,131 | $3.2M | $3.3M | $2.8M | $3.0M |
| Total Equity | $976,242 | $3.5M | $1.3M | $1.7M | $3.5M |
| Retained Earnings | -$5.4M | -$9.5M | -$13.2M | -$16.0M | -$19.2M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 10:37am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-473,975 | $-741,450 | -$3.0M | -$2.1M | $-181,464 |
| Capital Expenditure | $-25,442 | -$1.3M | $-212,523 | $-74,110 | $-985 |
| Free Cash Flow | $-499,417 | -$2.1M | -$3.2M | -$2.2M | $-182,450 |
| Acquisitions (net) | $0 | $199,527 | $-50,486 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $217 | $4.7M | -$2.2M | $-14,306 | $19,018 |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 10:37am (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | +100.0% | — |
| Operating Income Growth | -29.3% | +95.8% | -2,442.0% | +96.3% |
| Net Income Growth | -119.2% | +97.0% | -2,189.5% | +96.4% |
| EBITDA Growth | -26.1% | +96.1% | -2,331.5% | +96.1% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 7:51am (1h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2005-01-03 | CAPPELLO ALEXANDER L | J-Other | 25,000.00 | $0.20 | $5,000 |
| 2004-03-31 | CAPPELLO ALEXANDER L | C-Conversion | 0.00 | $0.24 | $0 |
| 2004-03-31 | CAPPELLO ALEXANDER L | C-Conversion | 155,945.00 | $0.24 | $37,427 |
| 2003-12-31 | CAPPELLO ALEXANDER L | J-Other | 12,948.00 | $0.25 | $3,237 |
| 2003-12-31 | CAPPELLO ALEXANDER L | A-Award | 30,000.00 | $0.42 | $12,600 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ADVB — it's generated by the pipeline (
market-narrative step).
No community reviews yet for ADVB.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30